# 1 2

# Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response to Celecoxib and Naproxen

- 3 Katherine N. Theken, PharmD, PhD;<sup>1,2\*</sup> Soumita Ghosh, PhD;<sup>1</sup> Carsten Skarke, MD;<sup>1,3</sup> Susanne
- 4 Fries, MD;<sup>1</sup> Nicholas F. Lahens, PhD;<sup>1</sup> Dimitra Sarantopoulou, MS;<sup>1,4</sup> Gregory R. Grant, PhD;<sup>1,5</sup>
- 5 Garret A. FitzGerald, MD;<sup>1,3</sup> Tilo Grosser, MD<sup>1,3,6</sup>\*
- <sup>6</sup> <sup>1</sup> Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University
- 7 of Pennsylvania, Philadelphia, PA, United States
- <sup>2</sup> Department of Oral and Maxillofacial Surgery and Pharmacology, School of Dental Medicine,
- 9 University of Pennsylvania, Philadelphia, PA, United States
- <sup>3</sup> Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- <sup>4</sup> Current address: National Institute on Aging, National Institutes of Health, Baltimore, MD,
- 12 United States
- <sup>5</sup> Department of Genetics, University of Pennsylvania, Philadelphia, PA, United States
- <sup>6</sup> Department of Translational Pharmacology, EWL School of Medicine, Bielefeld University,
- 15 Bielefeld, Germany
- 16 Short Title: COX2 Inhibition and Hypertensive Effects of NSAIDs

# 17 **\*Corresponding Authors:**

- 18 Katherine N. Theken, PharmD, PhD
- 19 Department of Oral and Maxillofacial Surgery and Pharmacology
- 20 School of Dental Medicine, University of Pennsylvania
- 21 240 S 40<sup>th</sup> St
- 22 Room 531 Levy
- 23 Philadelphia, PA 19104
- 24 Phone: +1 215 898-7470
- 25 Email: ktheken@pennmedicine.upenn.edu
- 26
- 27 Tilo Grosser, MD
- 28 Department of Translational Pharmacology
- 29 EWL School of Medicine
- 30 Bielefeld University
- 31 Universitätsstrasse 25
- 32 Bielefeld, Germany
- 33
- 34 Phone: +49 521 106-86800
- 35 Email: <u>tilo.grosser@uni-bielefeld.de</u>
- 36
- 37 Word Count: 4701

#### 38 Abstract:

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of adverse 39 cardiovascular events via suppression of cyclooxygenase (COX)-2-derived prostacyclin (PGI<sub>2</sub>) 40 41 formation in heart, vasculature, and kidney. The Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION) trial and other large 42 43 clinical studies compared the cardiovascular risk of traditional NSAIDs (i.e. naproxen), which 44 inhibit both COX isozymes, with NSAIDs selective for COX-2 (i.e. celecoxib). However, whether pharmacologically equipotent doses were used - that is, whether a similar degree of COX-2 45 46 inhibition was achieved - was not considered. We compared drug target inhibition and blood 47 pressure response to celecoxib at the dose used by most patients in PRECISION with the 48 lowest recommended naproxen dose for osteoarthritis, which is lower than the dose used in PRECISION. 49

50 **Methods:** Sixteen healthy participants (19-61 years) were treated with celecoxib (100 mg every 51 12h), naproxen (250 mg every 12h), or placebo administered twice daily for seven days in a 52 double-blind, crossover design randomized by order. On Day 7 when drug levels had reached 53 steady state, the degree of COX inhibition was assessed *ex vivo* and *in vivo*. Ambulatory blood 54 pressure was measured throughout the final 12h dosing interval.

55 **Results:** Both NSAIDs inhibited COX-2 activity relative to placebo, but naproxen inhibited

56 COX-2 activity to a greater degree ( $62.9\pm21.7\%$ ) than celecoxib ( $35.7\pm25.2\%$ ; p<0.05).

57 Similarly, naproxen treatment inhibited  $PGI_2$  formation *in vivo* (48.0±24.9%) to a greater degree

than celecoxib (26.7±24.6%; p<0.05). Naproxen significantly increased blood pressure

59 compared to celecoxib (differences in least-square means of mean arterial pressure: 2.5 mm Hg

60 (95% CI: 1.5, 3.5); systolic blood pressure: 4.0 mm Hg (95% CI: 2.9, 5.1); diastolic blood

61 pressure: 1.8 mm Hg (95% CI: 0.8, 2.8); p<0.05 for all). The difference in systolic blood

62 pressure relative to placebo was associated with the degree of COX-2 inhibition (p<0.05).

Conclusions: Celecoxib 200 mg/day inhibited COX-2 activity to a lesser degree than naproxen
 500 mg/day, resulting in a less pronounced blood pressure increase. While the PRECISION
 trial concluded the non-inferiority of celecoxib regarding cardiovascular risk, this is based on a
 comparison of doses that are not equipotent.

- 67 ClinicalTrials.gov identifier: NCT02502006 (https://clinicaltrials.gov/study/NCT02502006)
- 68

# 69 Clinical Perspective

- Naproxen 250 mg twice a day inhibited COX-2 activity to a greater degree than
   celecoxib 100 mg twice a day.
- The degree of COX-2 inhibition was associated with the increase in systolic blood
   pressure with NSAID treatment relative to placebo.
- Dose and its pharmacological potency achieved *in vivo* should be considered when
   evaluating the relative cardiovascular safety of COX-2-selective vs. non-selective
   NSAIDs.

## 77 Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used 78 medications worldwide and the opioid crisis has placed a new emphasis on their use.<sup>1,2</sup> 79 Approximately 20% of adults in the United States receive at least one NSAID prescription per 80 year<sup>3</sup>, and 12% of adults in the United States reported using NSAIDs chronically, i.e. more than 81 three times weekly for more than three months.<sup>4</sup> Consumption of NSAIDs in individuals at risk 82 for musculoskeletal injuries is even more common.<sup>5-7</sup> Given the high prevalence of chronic pain 83 in the United States – more than 100 million Americans suffer from chronic pain<sup>8</sup> – NSAIDs are 84 85 an important non-addictive option for pain relief. Optimizing NSAID therapy is one strategy to address the current opioid crisis,<sup>2</sup> and rates of NSAID use have increased in recent years as 86 opioid prescriptions have declined.<sup>9</sup> Although they lack the addictive potential of opioids, 87 NSAIDs have the potential to cause serious, and in some cases, life-threatening adverse 88 events, including gastrointestinal bleeding, renal dysfunction, hypertension, and thrombotic 89 90 cardiovascular events.<sup>10</sup> Undetected blood pressure (BP) increases that may impact cardiovascular morbidity and mortality at the population level are a particular concern.<sup>11</sup> 91

92 NSAIDs exert their analgesic and anti-inflammatory effects via inhibition of 93 cyclooxygenase (COX)-1 and/or COX-2, enzymes that catalyze the first committed step in prostaglandin (PG) synthesis. PGs produce a diverse array of biologic effects via activation of 94 prostanoid receptors and play important roles in a variety of pathologic and homeostatic 95 processes.<sup>12</sup> The risk of thrombotic events associated with the use of NSAIDs, particularly those 96 selective for COX-2, is mediated via suppression of COX-2-derived prostacyclin (PGI<sub>2</sub>) 97 formation in endothelial and vascular smooth muscle cells.<sup>13,14</sup> PGI<sub>2</sub> possesses potent anti-98 thrombotic and vasodilatory effects, and thus acts as a general inhibitor of platelet activation in 99 vivo.12 Non-selective NSAIDs also inhibit COX-2 in the vasculature, but the associated risk of 100 thrombosis is mitigated to some extent by inhibition of formation of thromboxane A<sub>2</sub> (TxA<sub>2</sub>), a 101 COX-1-derived PG released by activated platelets that promotes platelet activation and 102 aggregation.<sup>10,15</sup> In addition to their effects on vascular PG production, NSAIDs inhibit renal PG 103 formation, resulting in sodium retention and BP increases, which may further augment 104 cardiovascular risk.<sup>10,15,16</sup> 105

One of the largest (N=24,081) outcome studies to date, the Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen trial (PRECISION), compared the safety of the COX-2 selective NSAID, celecoxib (100 to 200 mg twice a day) , and two traditional NSAIDs, naproxen (375 to 500 mg twice a day) and ibuprofen (600 to 800 mg

110 three times a day), in osteoarthritis (90%) and rheumatoid arthritis (10%) patients. PRECISION 111 concluded that the cardiovascular safety of moderate doses of celecoxib (average dose: 112 209±37 mg/day) was noninferior to naproxen (average dose: 852±103 mg/day) or ibuprofen (average dose: 2045±246 mg/day).<sup>17</sup> However, a secondary on-treatment analysis of 113 PRECISION showed a lower risk of cardiorenal events in the celecoxib group than the ibuprofen 114 and naproxen groups.<sup>18</sup> Similarly, a pre-specified substudy (PRECISION-ABPM) reported that 115 the percentage of patients with normal baseline blood pressure who developed hypertension 116 was significantly greater in patients treated with naproxen (19%) or ibuprofen (23%), than with 117 celecoxib (10%).<sup>19</sup> However, the degree of COX-2 inhibition attained has never been assessed 118 in clinical outcome trials, and thus it is unknown whether the doses employed in PRECISION 119 were equipotent. Here, we compared the pharmacologic potency of celecoxib, 200 mg/day (the 120 highest dose allowed for osteoarthritis and roughly the average daily dose in PRECISION), with 121 naproxen, 500 mg/day (the lowest recommended dose for osteoarthritis and approximately 40% 122 123 lower than the average daily dose in PRECISION), and how this relates to blood pressure response to NSAIDs in a highly controlled study in apparently healthy volunteers. 124

#### 125

#### 126 Methods

# 127 Participants

Men and women ( $\geq$ 18 years of age) who were in good health based on medical history. 128 129 physical examination, vital signs, and laboratory tests were enrolled. Participants were excluded if they were pregnant or nursing a child, smoked or used nicotine-containing products, 130 were obese (body mass index (BMI) > 30 kg/m<sup>2</sup>), had a history of significant cardiovascular, 131 gastrointestinal, renal, hepatic, respiratory, immune, endocrine, hematologic, or neurological 132 133 disease, a history of cancer within the last 5 years, or a coagulation or bleeding disorder, were 134 sensitive or allergic to celecoxib, naproxen, aspirin, or other NSAIDs, or had used NSAIDs 135 (including acetaminophen), dietary or herbal supplements containing salicylates, Vitamin E, fish 136 oil, or any other herbal supplements, within 14 days of study drug administration.

#### 137 Study procedures

The study protocol was approved by the University of Pennsylvania Institutional Review Board (IRB#820715; ClinicalTrials.gov: NCT02502006), and all participants provided informed consent. The study was a randomized, double-blind, three-way crossover study comparing the degree of COX inhibition and the blood pressure response at steady state following treatment

with celecoxib (100 mg twice daily), naproxen (250 mg twice daily), or placebo (twice daily) for 7
days. Prior to beginning treatment, all participants attended a screening visit to obtain a
complete medical history and confirm eligibility. They were asked to abstain from analgesics,
including products containing NSAIDs (including aspirin and acetaminophen), high dose
vitamins, and nutritional supplements until study completion.

147 On the first day of each treatment phase, baseline blood and urine samples were collected, and participants were given a blisterpack with blinded study medication to be taken by 148 mouth twice daily on an outpatient basis. Study medication was blinded by over-encapsulation 149 by the University of Pennsylvania Investigational Drug Service. On the morning of day 7, 150 151 participants returned to clinic for a 12-hour visit for pharmacokinetic-pharmacodynamic (PK-PD) sampling. An ambulatory blood pressure monitor (ABPM, Spacelabs 90207), which recorded 152 153 blood pressure every 15 minutes throughout the study visit, was placed on the non-dominant upper arm. Blood and urine samples were collected (T=0), and the final dose of study 154 155 medication was administered. Additional samples were collected 0.5 (blood only), 1, 2, 4, 8, 156 and 12 hours after study medication administration. Participants were discharged after the 12hour sample collection. These study visits were repeated for the next two treatment phases, 157 158 with a washout period of at least 2 weeks between each treatment phase.

159 Study data were collected and managed using REDCap (Research Electronic Data 160 Capture) hosted at the University of Pennsylvania Perelman School of Medicine.<sup>20,21</sup>

#### 161 Quantification of COX activity and plasma drug concentrations

162 COX-1 activity *ex vivo* was evaluated by quantifying serum thromboxane  $B_2$  levels, as 163 previously described.<sup>22</sup> Briefly, whole blood was collected into vacuum tubes containing clot 164 activator and incubated in a water bath at 37°C for 1 hour. Serum was separated by 165 centrifugation and stored at -80°C until analysis by liquid chromatography-tandem mass 166 spectrometry (LC-MS/MS).

167 COX-2 activity *ex vivo* was evaluated by quantifying plasma  $PGE_2$  levels following 168 lipopolysaccharide (LPS) stimulation in whole blood, as previously described.<sup>23</sup> Briefly, 169 heparinized whole blood was treated with aspirin (1 mM) and incubated at room temperature for 170 15 minutes. LPS (E. coli, serotype O111:B4, 10 µg/ml whole blood) was added, and the sample 171 was incubated in a water bath at 37°C for 24 hours. Plasma was separated by centrifugation 172 and stored at -80°C until analysis by LC-MS/MS.

173 COX activity *in vivo* was determined by quantification of urinary prostanoid metabolites 174 by LC-MS/MS as previously described.<sup>14</sup> Systemic production of PGI<sub>2</sub>, PGE<sub>2</sub>, PGD<sub>2</sub>, and

thromboxane (Tx)  $A_2$  was determined by quantifying their major urinary metabolites: 2,3-dinor 6keto-PGF<sub>1a</sub> (PGIM), 7-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid (PGEM), 11,15dioxo-9a-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (PGDM), and 2,3-dinor TxB<sub>2</sub> (TxM), respectively. Results were normalized to urinary creatinine measured by LC-MS/MS.

Plasma concentrations of celecoxib and naproxen were quantified by LC-MS/MS as
 previously described.<sup>24</sup>

#### 181 Statistical analysis

Measurements of COX activity ex vivo and urinary PG metabolite levels were normalized 182 to the mean value during the placebo phase for each subject to calculate the percent of COX 183 inhibition relative to placebo. Area-under-the-curve from T=0 to T=12 hours (AUC) was 184 185 calculated as a measure of the degree of COX inhibition throughout the dosing interval. The 186 degree of COX inhibition was compared by paired t-test. The effect of treatment on COX 187 activity and ABP over time was analyzed by linear mixed effect modeling using the Ime4 R package,<sup>25</sup> including time and treatment as main effects and participant as a random effect. 188 189 The relationship between change in SBP and COX inhibition over the 12-hour dosing interval 190 was evaluated by linear regression. P<0.05 was considered statistically significant. Statistical analyses were performed in R (version 4.3.1). 191

192

#### 193 Results

The study cohort included 16 healthy adults (9 men, 7 women) with a mean age of 34.7±13.4 years. Baseline demographic and clinical characteristics are shown in Table 1. Biochemical measures were evaluated in all participants. One participant was excluded from ABP analysis due to ABPM malfunction and incomplete data.

Naproxen 250 mg twice daily inhibited COX-1 activity and COX-2 activity ex vivo by 198 95.3±4.4% and 62.9±21.7%, respectively, while celecoxib 100 mg twice daily had minimal 199 effects on COX-1 activity ex vivo and inhibited COX-2 activity ex vivo by 35.7±25.2% over the 200 201 12-hour dosing interval (Figure 1). Similar results were observed for COX activity in vivo, assessed by urinary PG metabolite concentrations. TxM (an index of COX-1 activity) was 202 203 inhibited by 68.2±18.7% with naproxen treatment and 8.9±35.7% with celecoxib treatment. 204 PGIM (an index of COX-2 activity in vivo) was inhibited by 48.0±24.9% with naproxen treatment and 26.7±24.6% with celecoxib treatment. With all functional parameters, the degree of COX 205 206 inhibition was significantly greater with naproxen treatment than celecoxib treatment (p<0.05). The maximum plasma concentration ( $C_{max}$ ) of naproxen was 228±45.1 µM, and the time to 207

208 maximum plasma concentration ( $t_{max}$ ) was 1.8±1.2 h after administration. For celecoxib,  $C_{max}$ 209 was 1.28±0.55 µM, and  $t_{max}$  was 2.3±1.2 h.

210 During the placebo phase, average MAP, SBP, and DBP were 89.7±8.7 mmHg, 124.1±11.2 mm Hg, and 73.3±8.7 mm Hg, respectively. NSAID treatment affected MAP and 211 212 SBP over the 12-hour dosing interval (Figure 2). Naproxen treatment significantly increased MAP (Difference in LS means: 3.1 mm Hg (95% CI: 2.1, 4.1); p<0.05), SBP (Difference in LS 213 means: 2.9 mm Hg (95% CI: 1.8, 4.0); p<0.05) and DBP (Difference in LS means: 3.2 mm Hg 214 (95% CI: 2.2, 4.2); p<0.05) relative to placebo. In contrast, celecoxib treatment did not affect 215 216 MAP (Difference in LS means: 0.6 mm Hg (95% CI: -0.3, 1.6); p=0.28), but significantly decreased SBP (Difference in LS means: -1.1 mm Hg (95% CI: -2.2, 0.04); p<0.05) and 217 increased DBP (Difference in LS means: 1.4 mm Hg (95% CI: 0.4, 2.4); p<0.05) relative to 218 placebo. Compared to celecoxib, naproxen significantly increased MAP (Difference in LS 219 means: 2.5 mm Hg (95% CI: 1.5, 3.5); p<0.05), SBP (Difference in LS means: 4.0 mm Hg (95% 220 221 Cl: 2.9, 5.1); p<0.05), and DBP (Difference in LS means: 1.8 mm Hg (95% Cl: 0.8, 2.8); p<0.05). 222

Linear regression was performed to determine whether the degree of COX-1 or COX-2 inhibition *ex vivo* predicted the difference in SBP with NSAID treatment relative to placebo (Figure 3). COX-2 inhibition *ex vivo* was a predictor of difference in SBP ( $\beta$ =-10.38, 95% confidence interval=-19.27 to -1.482, R<sup>2</sup>=0.1694, F(1,28)=5.710, p=0.0238), but COX-1 inhibition *ex vivo* was not significantly associated with difference in SBP ( $\beta$ =-2.194, 95% confidence interval=-6.068 to 1.680, R<sup>2</sup>=0.04587, F(1,28)=1.346, p=0.2558).

229

### 230 Discussion

Given the high prevalence of chronic pain in the United States,<sup>26</sup> NSAIDs are an 231 important non-addictive option for pain relief.<sup>2</sup> Currently, it is recommended that NSAIDs be 232 avoided or used only for a limited duration at the lowest possible dose in patients considered at 233 high cardiovascular risk.<sup>27</sup> As COX-2 inhibition mechanistically underlies the cardiovascular 234 risk, a key question remains whether differences in the cardiovascular safety profile exist 235 236 between traditional NSAIDs (i.e. naproxen) which inhibit both COX-1 and COX-2, and selective inhibitors of COX-2 (i.e. celecoxib).<sup>28</sup> The largest comparator trial to address this question, 237 238 PRECISION, indicated that celecoxib is noninferior to naproxen and ibuprofen with regard to cardiovascular risk.<sup>17</sup> Importantly, the dose of celecoxib was limited to 200 mg/day in 239 240 osteoarthritis patients enrolled in PRECISION, which made up the vast majority of the study

241 population. Limiting the dose in osteoarthritis patients had been a regulatory response to the 242 cardiovascular hazard detected in previous randomized controlled trials. Although the 243 pharmacological potency of celecoxib measured with isolated COX-2 enzyme or cellular preparations *in vitro* is higher than that of naproxen,<sup>29</sup> here we demonstrate that the average 244 daily dose of celecoxib used in the PRECISION trial inhibited COX-2 activity in vivo to a lesser 245 246 degree than a low dose of naproxen and that this impacted the blood pressure response to 247 NSAID treatment. Our results underscore the importance of considering dose and pharmacoequivalence in vivo in comparisons of safety among drugs of the same class. 248

249 Only a small number of clinical trials have prospectively assessed the effects of COX inhibition on BP control. Based on these studies, increases of 3-5 mmHg in SBP can be 250 expected.<sup>16</sup> In our cohort, naproxen treatment increased SBP relative to placebo (2.9 mm Hg 251 (95% CI: 1.8,4.0)) to a greater extent than celecoxib treatment (-1.1 mm Hg (95% CI: -2.2,-252 0.04)) over the 12-hour dosing interval. This difference is similar to what was observed in 253 254 PRECISION-ABPM, where the change in SBP from baseline after 4 months of treatment was -0.18±9.400 mm Hg among celecoxib-treated patients and 1.91±9.796 mm Hg among naproxen-255 treated patients.<sup>19</sup> Notably, we observed that the difference in SBP was associated with the 256 degree of COX-2 inhibition on NSAID treatment, consistent with the inhibition of COX-2-257 258 mediated PGI<sub>2</sub> formation as the primary mechanism underlying the increased cardiovascular 259 risk associated with NSAID use.

260 Although naproxen increased SBP to a greater extent than celecoxib in our study cohort, 261 the blood pressure response to NSAID treatment was heterogeneous among individual patients. The effects of COX inhibition on blood pressure control are complex, which may contribute to 262 the variable occurrence of hypertension on NSAIDs.<sup>10,15,16,30</sup> In the renal cortex, the production 263 of vasodilatory PGE<sub>2</sub> and PGI<sub>2</sub> maintain the patency of adjacent afferent arterioles,<sup>16,31</sup> and 264 COX-2 expression in renal medullary interstitial cells play an important role in the adaptive 265 regulation of blood pressure in response to high salt diet and dehydration.<sup>32-34</sup> COX inhibition in 266 these regions of the kidney contributes to the decline in glomerular filtration rate and elevations 267 in blood pressure observed in patients who take NSAIDs. However, dynamic expression of 268 COX-2 in the macula densa system is a component of the tubuloglomerular feedback 269 mechanism which promotes renin release.35-37 Inhibition of COX-2 in these cells would 270 counteract the hypertensive effects of renin-angiotensin system activation. Thus, the effect of 271 NSAID treatment on blood pressure reflects the complex interplay among these regulatory 272 273 systems. Interestingly, we observed that an individual participant's response was similar to both 274 drugs, suggesting that patient-specific factors may contribute to interindividual heterogeneity in

the response to NSAIDs. Future studies are necessary to elucidate the factors that contribute to
an individual patient's risk of hypertension and other cardiovascular adverse effects with NSAID
treatment.

There are limitations to our study. The small sample size limits our ability to 278 comprehensively investigate the factors that contribute to the blood pressure response to 279 NSAIDs. The study cohort included only healthy adults, most of whom were relatively young. 280 281 Although this limits potential confounding due to effects of age and comorbidities, it precludes interrogation of the influence of these factors on the blood pressure response to NSAID 282 283 treatment. Finally, we compared only one dose level of naproxen and celecoxib, which limits 284 our ability to extrapolate our results to higher doses or other NSAIDs. Despite these limitations, our results provide mechanistic insight into the outcome of PRECISION. 285

In conclusion, our results demonstrate that naproxen 500 mg/day inhibits COX-2 activity to a greater degree than celecoxib 200 mg/day and that the degree of COX-2 inhibition is associated with the blood pressure response to NSAID treatment. While PRECISION concluded non-inferiority of celecoxib compared to naproxen with regard to cardiovascular risk, this is based on a comparison of doses that are not equipotent.

Characteristic	Study Cohort
N (Men/Women)	16 (9/7)
Age	34.7±13.4 years (range: 19-61 years)
Race	
White	9
Black/African American	4
Asian	1
Other	2
Ethnicity	
Non-Hispanic	13
Hispanic	3
Body mass index	22.6±1.9 kg/m <sup>2</sup>
Lab values	
Total cholesterol	166.9±27.6 mg/dl
Triglycerides	70.9±24.4 mg/dl
LDL	94.7±22.9 mg/dl
HDL	58.1±13.3 mg/dl
Serum creatinine	0.83±0.14 mg/dl
Systolic blood pressure	115.3±8.9 mm Hg
Diastolic blood pressure	69.8±9.5 mm Hg
Heart rate	65.7±9.8 bpm

292 **Table 1.** Baseline characteristics of study participants.

293

# 295 Figures

Figure 1. Comparison of (A) COX-1 inhibition *ex vivo* and (B) *in vivo* and (C) COX-2 inhibition *ex vivo* and (D) *in vivo* by treatment. Plasma concentrations of (E) celecoxib and (F) naproxen

over time. Dosing occurred at 8:00 AM  $\pm$  15 min. Data are shown as mean  $\pm$  SEM. \*p<0.05



Figure 2. Comparison of (A) SBP, (B) DBP, and (C) MAP over 12-hour dosing interval by treatment. Data are shown as mean  $\pm$  SEM. (D) Change in SBP relative to placebo with celecoxib and naproxen treatment. Dosing occurred at 8:00 AM  $\pm$  15 min. \*p<0.05



**Figure 3.** Relationship between degree of COX-1 and COX-2 inhibition *ex vivo* and change in systolic blood pressure.



• Celecoxib 
• Naproxen

# 309 Sources of Funding

Research reported in this publication was supported by a Translational Medicine and Therapeutics Postdoctoral Fellowship from the PhRMA Foundation, and funding from the National Heart, Lung, and the Blood Institute (HL117798) and National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001878). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## 316 Acknowledgements

- 317 Dr. FitzGerald is the McNeil Professor of Translational Medicine and Therapeutics and held a
- 318 Merit Award from the American Heart Association. C.S. is the Robert L. McNeil Jr. Fellow in
- 319 Translational Medicine and Therapeutics.

### 320 Disclosures

K.N.T., S.G., C.S., S.F., N.F.L., D.S., G.R.G., G.A.F., and T.G. have nothing to disclose.

In: Phillips JK, Ford MA, Bonnie RJ, eds. Pain Management and the Opioid Epidemic: Balancing

## 322 References

1.

323

324 Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington (DC); 2017. 325 2. Grosser T, Woolf CJ, FitzGerald GA. Time for nonaddictive relief of pain. Science. 2017;355:1026-326 1027. doi: 10.1126/science.aan0088 327 Stagnitti MN. Trends in Outpatient Prescription Analgesics Utilization and Expenditures for the 3. 328 U.S. Civilian Noninstitutionalized Population, 1996 and 2006. Medical Expenditure Panel Survey. 329 https://meps.ahrg.gov/data\_files/publications/st235/stat235.shtml. 2009. Accessed 1/5/2024. 330 Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-4. inflammatory drugs in the general U.S. population. *Pharmacoepidemiology and drug safety*. 331 332 2014;23:43-50. doi: 10.1002/pds.3463 333 5. Gorski T, Cadore EL, Pinto SS, da Silva EM, Correa CS, Beltrami FG, Kruel LF. Use of NSAIDs in 334 triathletes: prevalence, level of awareness and reasons for use. British journal of sports medicine. 2011;45:85-90. doi: 10.1136/bjsm.2009.062166 335 336 6. Kuster M, Renner B, Oppel P, Niederweis U, Brune K. Consumption of analgesics before a 337 marathon and the incidence of cardiovascular, gastrointestinal and renal problems: a cohort 338 study. BMJ open. 2013;3. doi: 10.1136/bmjopen-2012-002090 339 7. Walker LA, Zambraski EJ, Williams RF. Widespread Use of Prescription Nonsteroidal Anti-340 Inflammatory Drugs Among U.S. Army Active Duty Soldiers. Military medicine. 2017;182:e1709-341 e1712. doi: 10.7205/MILMED-D-16-00183 342 8. Institute of Medicine (US) Committee on Advancing Pain Research C, and Education. . Relieving 343 Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011. 344 doi: NBK91497 [bookaccession] 345 9. Keshwani S, Smith SM, Brown J, Lo-Ciganic WH, Yang S, Smolinski NE, Hincapie-Castillo JM. 346 Trends in Prescribing of Non-steroidal Anti-inflammatory Medications in the US Ambulatory 347 Care Setting From 2006 to 2016. The journal of pain : official journal of the American Pain 348 Society. 2023. doi: 10.1016/j.jpain.2023.06.008 349 10. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17-33. doi: 10.1146/annurev-med-011209-153129 350 351 11. Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal 352 353 antiinflammatory drugs. Cardiovasc Ther. 2012;30:342-350. doi: 10.1111/j.1755-354 5922.2011.00283.x 355 12. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid 356 Res. 2009;50 Suppl:S423-428. doi: 10.1194/jlr.R800094-JLR200 357 Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role 13. 358 of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541. 359 doi: 10.1126/science.1068711 360 14. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Pure E, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 361 362 2012;4:132ra154. doi: 10.1126/scitranslmed.3003787 363 15. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 364 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15. doi: 365 10.1172/JCI27291 366 16. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, 367 Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, 368 hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.

369 Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, Graham DY, Borer JS, 17. 370 Wisniewski LM, Wolski KE, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for 371 Arthritis. N Engl J Med. 2016;375:2519-2529. doi: 10.1056/NEJMoa1611593 372 18. Obeid S, Libby P, Husni E, Wang Q, Wisniewski LM, Davey DA, Wolski KE, Xia F, Bao W, Walker C, 373 et al. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: 374 insights from the PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022;8:611-621. doi: 375 10.1093/ehjcvp/pvac015 376 Ruschitzka F, Borer JS, Krum H, Flammer AJ, Yeomans ND, Libby P, Luscher TF, Solomon DH, 19. 377 Husni ME, Graham DY, et al. Differential blood pressure effects of ibuprofen, naproxen, and 378 celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of 379 Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure 380 Measurement) Trial. European heart journal. 2017. doi: 10.1093/eurheartj/ehx508 20. 381 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture 382 (REDCap)--a metadata-driven methodology and workflow process for providing translational 383 research informatics support. J Biomed Inform. 2009;42:377-381. doi: 10.1016/j.jbi.2008.08.010 384 21. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua 385 F, Kirby J, et al. The REDCap consortium: Building an international community of software 386 platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208 387 22. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372. 388 389 23. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta 390 F, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and 391 monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 392 1999;290:276-280. 393 24. Li X, Fries S, Li R, Lawson JA, Propert KJ, Diamond SL, Blair IA, FitzGerald GA, Grosser T. 394 Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by 395 nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2014;111:16830-16835. doi: 396 10.1073/pnas.1406997111 397 25. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using Ime4. Journal 398 of Statistical Software. 2015;67:1 - 48. doi: 10.18637/jss.v067.i01 Institute of Medicine (U.S.). Committee on Advancing Pain Research Care and Education. 399 26. 400 Relieving pain in America : a blueprint for transforming prevention, care, education, and 401 research. Washington, D.C.: National Academies Press; 2011. 402 27. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal 403 antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart 404 Association. Circulation. 2007;115:1634-1642. doi: 10.1161/CIRCULATIONAHA.106.181424 405 28. Grosser T, Ricciotti E, FitzGerald GA. The Cardiovascular Pharmacology of Nonsteroidal Anti-406 inflammatory Drugs. Trends Pharmacol Sci. 2017;38:(in press). 407 29. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities 408 for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal 409 toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563-7568. 410 30. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in 411 hypertensive patients. Cardiol Rev. 2011;19:184-191. doi: 10.1097/CRD.0b013e31821ddcf4 412 Terragno NA, Terragno DA, McGiff JC. Contribution of prostaglandins to the renal circulation in 31. 413 conscious, anesthetized, and laparotomized dogs. Circulation research. 1977;40:590-595. 414 32. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar 415 to traditional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;111:64-67.

- 416 33. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of
  417 cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. *J Clin Invest*.
  418 2002;110:61-69.
- 41934.Zewde T, Mattson DL. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-420sensitive hypertension. Hypertension. 2004;44:424-428.
- 421 35. FitzGerald GA, Hossmann V, Hummerich W, Konrads A. The renin--kallikrein--prostaglandin
- 422 system: plasma active and inactive renin and urinary kallikrein during prostacyclin infusion in 423 man. *Prostaglandins Med.* 1980;5:445-456.
- 424 36. Peti-Peterdi J, Komlosi P, Fuson AL, Guan Y, Schneider A, Qi Z, Redha R, Rosivall L, Breyer MD,
  425 Bell PD. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. *J Clin*426 *Invest*. 2003;112:76-82.
- 37. Stichtenoth DO, Marhauer V, Tsikas D, Gutzki FM, Frolich JC. Effects of specific COX-2-inhibition
  on renin release and renal and systemic prostanoid synthesis in healthy volunteers. *Kidney Int.*2005;68:2197-2207.